Healthcare provider profile · identity verified

Domingo Gilberto Rodriguez, MD

Internal Medicine · HATO REY, PR · NPI 1376649749

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	478	126
Simvastatin	Simvastatin	405	74
Atorvastatin Calcium	Atorvastatin Calcium	357	86
Synthroid	Levothyroxine Sodium	354	77
Metformin Hcl	Metformin Hcl	328	66
Losartan Potassium	Losartan Potassium	324	71
Rosuvastatin Calcium	Rosuvastatin Calcium	266	74
Amlodipine Besylate	Amlodipine Besylate	263	61
Metoprolol Succinate	Metoprolol Succinate	258	48
Glimepiride	Glimepiride	236	43
Famotidine	Famotidine	149	55
Levothyroxine Sodium	Levothyroxine Sodium	149	39
Lisinopril	Lisinopril	132	25
Pantoprazole Sodium	Pantoprazole Sodium	124	41
Carvedilol	Carvedilol	113	20
Candesartan Cilexetil	Candesartan Cilexetil	111	25
Omeprazole	Omeprazole	99	29
Irbesartan	Irbesartan	97	31
Clopidogrel	Clopidogrel Bisulfate	94	21
Ezetimibe	Ezetimibe	86	22
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	86	24
Clonazepam	Clonazepam	85	28
Azithromycin	Azithromycin	83	63
Montelukast Sodium	Montelukast Sodium	78	29
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	77	18
Hydrochlorothiazide	Hydrochlorothiazide	76	16
Tizanidine Hcl	Tizanidine Hcl	75	42
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	74	12
Diclofenac Potassium	Diclofenac Potassium	73	51
Levofloxacin	Levofloxacin	72	60
Tamsulosin Hcl	Tamsulosin Hcl	67	20
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	64	13
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	63	suppressed
Enalapril Maleate	Enalapril Maleate	59	11
Diclofenac Sodium Er	Diclofenac Sodium	55	32
Temazepam	Temazepam	55	20
Pregabalin	Pregabalin	51	12
Allopurinol	Allopurinol	50	11
Atenolol	Atenolol	50	suppressed
Farxiga	Dapagliflozin Propanediol	49	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	49	suppressed
Metformin Hcl Er	Metformin Hcl	49	12
Benazepril Hcl	Benazepril Hcl	47	11
Diclofenac Sodium	Diclofenac Sodium	46	37
Lansoprazole	Lansoprazole	46	11
Eliquis	Apixaban	45	12
Lantus	Insulin Glargine,hum.Rec.Anlog	41	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	40	suppressed
Sertraline Hcl	Sertraline Hcl	40	12
Xigduo Xr	Dapaglifloz Propaned/Metformin	40	suppressed
Donepezil Hcl	Donepezil Hcl	39	11
Fenofibrate	Fenofibrate	38	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	38	suppressed
Naproxen	Naproxen	38	17
Ciprofloxacin Hcl	Ciprofloxacin Hcl	37	34
Raloxifene Hcl	Raloxifene Hcl	37	suppressed
Alprazolam	Alprazolam	34	14
Janumet	Sitagliptin Phos/Metformin Hcl	34	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	34	suppressed
Warfarin Sodium	Warfarin Sodium	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	32	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	31	21
Isosorbide Mononitrate Er	Isosorbide Mononitrate	29	suppressed
Levetiracetam	Levetiracetam	29	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	28	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	27	19
Glipizide	Glipizide	27	suppressed
Furosemide	Furosemide	26	suppressed
Xarelto	Rivaroxaban	26	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	25	suppressed
Tramadol Hcl-Acetaminophen	Tramadol Hcl/Acetaminophen	25	19
Alendronate Sodium	Alendronate Sodium	23	11
Nabumetone	Nabumetone	23	13
Azelastine Hcl	Azelastine Hcl	22	22
Fenofibrate	Fenofibrate Nanocrystallized	22	suppressed
Finasteride	Finasteride	22	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	22	suppressed
Clonidine Hcl	Clonidine Hcl	19	suppressed
Humalog Mix 75-25	Insulin Lispro Protamin/Lispro	19	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	19	16
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Humulin N	Insulin Nph Human Isophane	18	suppressed
Meclizine Hcl	Meclizine Hcl	17	11
Carbidopa-Levodopa	Carbidopa/Levodopa	16	suppressed
Memantine Hcl	Memantine Hcl	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	15	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Fluconazole	Fluconazole	15	12
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Mometasone Furoate	Mometasone Furoate	15	15
Acebutolol Hcl	Acebutolol Hcl	14	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	14	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	14	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	12	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	11
Cilostazol	Cilostazol	12	suppressed
Digoxin	Digoxin	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	12	suppressed
Trandolapril	Trandolapril	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Etodolac Er	Etodolac	11	suppressed
Flecainide Acetate	Flecainide Acetate	11	suppressed
Humalog Mix 50-50 Kwikpen	Insulin Lispro Protamin/Lispro	11	suppressed
Lorazepam	Lorazepam	11	suppressed
Propranolol Hcl Er	Propranolol Hcl	11	suppressed
Sure Comfort	Syringe And Needle,insulin,1ml	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Tadalafil	Tadalafil	11	suppressed
Telmisartan	Telmisartan	11	suppressed
Tobramycin-Dexamethasone	Tobramycin/Dexamethasone	11	11

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error